CoChat

Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel

JORDY, ANDREAS BÔRSTING, BREITSCHAFT, ASTRID, CHRISTIANSEN, ERIK, GRANHALL, CHARLOTTE, HANSEN, CILIE W., HOUSHMAND-OREGAARD, AZADEH, BAEKDAL, TINE A. · 2018 · Diabetes
Cited by 13

The DOI matches its Crossref record.

Abstract

Semaglutide is a glucagon-like peptide (GLP-1) analog co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), to allow oral administration. The effect of oral semaglutide on the pharmacokinetics (PK) of the combined oral contraceptive (OC) ethinylestradiol (EE; 0.03 mg)/levonorgestrel (LN; 0.15 mg) was assessed in an open-label, one sequence crossover trial. Healthy post-menopausal females (n=25) received 8 days of OC alone and 8 days of OC with oral semaglutide (dose escalated to steady state at week 6: 1 week at 3 mg dose, 1 week at 7 mg dose, 4 weeks at 14 mg dose). Primary endpoints were the areas under the plasma concentration−time curve for EE and LN during a dosing interval (0−24 h) at steady state (AUC0−24h,SS). Secondary endpoints included other PK parameters, safety and tolerability. Total exposure of EE and LN were similar for OC alone vs. OC with oral semaglutide, and oral semaglutide did not affect the maximum plasma exposure (Cmax,SS) of EE or LN. AUC0−24h,SS and Cmax,SS ratios for EE and LN were within the predefined no effect interval (0.8−1.25) (Figure). Adverse events with oral semaglutide were consistent with previous trials and expected GLP-1 receptor agonist class effects. These data indicate that oral semaglutide did not affect the bioavailability of the combined OC. Disclosure: A. Bôrsting Jordy: Employee; Self; Novo Nordisk A/S. A. Breitschaft: None. E. Christiansen: Stock/Shareholder; Self; Novo Nordisk A/S. Employee; Self; Novo Nordisk A/S. C. Granhall: Employee; Self; Novo Nordisk A/S. C.W. Hansen: Employee; Self; Novo Nordisk A/S. A. Houshmand-Oregaard: Employee; Self; Novo Nordisk A/S. T.A. Baekdal: Stock/Shareholder; Self; Novo Nordisk A/S. Employee; Self; Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db18-1135-p

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 13

Metadata

Authors
JORDY, A. B., BREITSCHAFT, A., CHRISTIANSEN, E., GRANHALL, C., HANSEN, C. W., HOUSHMAND-OREGAARD, A., & BAEKDAL, T. A.
Venue
Diabetes
Published
2018-07-01
Volume
67
Issue
Supplement_1
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2808994737
Cited by
13
References
0
FWCI
1.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel. https://app.cochat.ai/papers/10.2337/db18-1135-p
The paper
JORDY, A. B., BREITSCHAFT, A., CHRISTIANSEN, E., GRANHALL, C., HANSEN, C. W., HOUSHMAND-OREGAARD, A., & BAEKDAL, T. A. (2018). Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel. Diabetes. https://doi.org/10.2337/db18-1135-p

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.